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The  present  article  is  the  ﬁrst ofﬁcial  report  of  ESPAMACS  (Spanish  Registry  for Mechanical  Circulatory
Support)  and  summarises  the registry  activity  from  when  it began  operating  in  October  2014–May  2016.
During  this  period,  369  mechanical  circulatory  support  devices,  implanted  in  18 different  centres  of  our
country  have  been  registered,  319  for short-term  support  (86.4%),  and  50  for  long-term  support  (13.6%).
An  analysis  is presented  of  the  proﬁle  of  the  assisted  patients  (demographic  data,  comorbidities,  under-
lying disease,  grade  of  heart  failure),  type  of  implanted  devices,  indications,  surgical  data  and  outcomes
(post-operative  outcome,  duration  of  support,  level  of achieving  objectives,  adverse  events,  survival,  and
causes of death).
© 2016  Sociedad  Espan˜ola  de  Cirugı´a  Tora´cica-Cardiovascular.  Published  by Elsevier  Espan˜a,  S.L.U.
This is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Este artículo  representa  el primer  informe  oﬁcial  de  ESPAMACS  (Registro  Nacional  Espan˜ol  de  Asisten-
cia  Mecánica  Circulatoria)  y en  él se  expone  la actividad  del registro  desde  que  comenzó  a  funcionar
en  octubre  de  2014  hasta  mayo  de  2016.  A  lo largo  de este  periodo  se  han registrado  369  dispositivos
de  asistencia  mecánica  circulatoria  implantados  en  18  centros  de nuestro  país,  319  de  corta  duración
(86.4%)  y 50  de  larga  duración  (13.6%).  Se  analiza  el perﬁl  de  los  pacientes  (datos  demográﬁcos,  comor-
bilidades,  enfermedad  de  base,  grado  de  insuﬁciencia  cardiaca),  el tipo  de dispositivos  implantados,  las
indicaciones,  los  datos  operatorios  y  los  resultados  (evolución  postoperatoria,  duración  del  soporte,  grado
de  consecución  de  objetivos,  efectos  adversos,  supervivencia  y causas  de  muerte).
©  2016  Sociedad  Espan˜ola  de Cirugı´a  Tora´cica-Cardiovascular.  Publicado  por Elsevier  Espan˜a,  S.L.U.
Este  es un  artı´culo  Open  Access  bajo  la licencia  CC  BY-NC-ND  (http://creativecommons.org/licenses/by-ntroductionConsidering the technological developments in mechanical
irculatory support (MCS) for patients with end-stage heart failure,
Abbreviations: EACTS, European Association of Cardiothoracic Surgery;
SPAMACS, Spanish Registry for mechanical circulatory support; EUROMACS,
uropean Registry for patients with mechanical circulatory support; IMACS,
SHLT Mechanical Assisted Circulatory Support Registry; INTERMACS, Interagency
egistry for Mechanically Assisted Circulatory Support; MCS, mechanical circulatory
upport; SECTCV, Spanish Society of Thoracic-Cardiovascular Surgery.
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134-0096/© 2016 Sociedad Espan˜ola de Cirugı´a Tora´cica-Cardiovascular. Published by E
http://creativecommons.org/licenses/by-nc-nd/4.0/).nc-nd/4.0/).
no clinician would doubt the need to register the events and data
emerging from the application of this therapy. Information about
the events in individual patients, as well as the statistical eva-
luation of different groups of patients and the information about
the functioning of devices over time can reveal a lot about the
safety of the applied therapy, freedom of adverse events and sur-
vival. Such data lead to adaptation of clinical practice based on
the registered outcomes, and may  result in new possibilities for
improvement and/or in technical innovation. Physicians may  use
data for patient selection and the development of bespoke treat-
ment strategies. Moreover, based on these data, the information to
patients and their next of kin about the expected outcomes of MCS
therapy may  become more accurate. The database offers individual
lsevier Espan˜a, S.L.U. This is an open access article under the CC BY-NC-ND license
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ospitals a tool for benchmarking, while researchers may  correlate
ata to gain science-based insights and deﬁne factors that inﬂuence
atient care and outcomes. The registry enables other stakeholders,
uch as the industry that produces the devices, to use data to initiate
nnovations, and to measure the results of those.
etrospective
As history shows, local registries, frequently developed by the
reating physician(s) or their in-hospital ICT (Information and
ommunication Technology) departments, became the source for
rofessionals to demonstrate their local achievements. Then, those
ho think big, and rightly so, develop initiatives to gather data on a
arger geographical scale. While in the USA hospitals were obliged
o provide data to INTERMACS, the Europeans created a voluntary
egistry, called EUROMACS, which connects with local and national
atabases. After an initiative of Prof. Roland Hetzer, EUROMACS
as founded in 2009 as a non-proﬁt association that functions
s a Committee of the European Association for Cardio-Thoracic
urgery. Forty-seven hospitals from 16 countries have now joined,
nd another 20 are taking steps to follow. The difference between
UROMACS and other registries is that EUROMACS provides data to
rofessionals who wish to carry out clinical and/or scientiﬁc ana-
yses. Further, data completeness checks by statisticians and on site
udits add to the quality of the data. The development of a near
eal-time dashboard will enable the participating sites to bench-
ark their outcomes by comparison with the anonymous data of
he other hospitals.
For reasons of different regulatory environments and spans of
ontrol, an agreement with the IMACS Registry sees to the provision
f data on a global level. Thus we have connected the world of MCS
rom the ground up, from local to global, expecting that the clinical
nd scientiﬁc data will enable us to learn how to improve the care
f patients with end-stage heart failure.
UROMACS organization
. Structure
As a Committee of the EACTS, EUROMACS is democratically
structured. Members of the executive board, which have ma-
ximal ﬁve members, are elected by the members for a period of
three years with a possibility to be re-elected for another three
years. The extended board has a maximum of seven members
and serves to reﬂect the diversity in nationalities of partici-
pants in the Registry. Extended board members are also chosen
for a period of maximal three years, twice. While the execu-
tive board sees to the execution of the aims of the organization,
the extended board approves the strategic planning, the annual
report and ﬁnancial report before it is sent to the members. The
executive board decided to appoint a managing director who
manages the day-to-day business of the organization and facili-
tates the work of the board.
. Providing data to clinicians and scientists
The ﬁrst aim of the EUROMACS registry is to provide data to
the community of clinicians and scientists.
1. On a regular basis (Annual Report)
2. Via the EUROMACS dashboard, after login
3. For scientiﬁc studies
4. Bespoke. E.g. for (national) statistics, for use on congresses.
The ﬁrst annual report was published in March 2015.1 The
second report is expected in the summer of 2016.Contributors of data, after they entered the EUROMACS re-
gistry by means of their password, will immediately see the pos-
sibility to open a dashboard with statistics. These statistics not
only provide general information about the number of cases iniov. 2016;23(S):22–25 23
the registry, it also shows comparisons between the data from
the hospital of the user with the entire EUROMACS database.
Further, any clinician or scientist can submit a study proposal
to the EUROMACS Committee, and request anonymous data
from the Registry. The applicant is asked to agree to use the
data for the sole purpose of the study they were asked for.
The data from EUROMACS were used for several studies and
publications.2
. Collection of data
A hospital that wishes to participate in the EUROMACS Re-
gistry is offered an agreement in which it accepts to provide
pseudo-anonymised base-line and follow-up data to the registry.
A unique password allows the responsible physician and/or data
manager to enter patient records and events. Three methods are
at the disposal of the participants:
a) Submitting the data patient per patient. This method is appro-
priate for hospitals that have a relatively low number of
implants per year.
b) Uploading from the local database. This method ﬁts hospitals
that historically have a local database in which they register
the details of the treatment of MCS  patients. The advantage is
that uploading these data avoids double data entry.
c) Regular data transfer from a national database, by means of a
unique secure link, to EUROMACS.
The EUROMACS data set consists of several groups:
• Base-line data such as sex, age, primary diagnosis, laboratory
data and blood circulation data before MCS  implantation. The
number of mandatory data is limited to seven.
• Quality of life data (EQ 5D).
• Peri-operative data.
• Any event after the implantation. A distinction is made
between major events and others, while routine follow-up is
registered when the patient has come in for a check-up. The
number of mandatory data is six.
The hospitals participating in the EUROMACS registry have
agreed to register events within 6 weeks after their occurrence.
Every six months, per June 30, and per December 31, they are
asked to conﬁrm that their data are up-to-date. The EUROMACS
management offers them an overview of their patients and, if
this would be the case, a break-down of missing data. After com-
pletion and correction the data are consolidated, from then on
they can be made available for analyses and studies.
. Quality control
Quality control, as referred to in the previous paragraph, con-
sists of the statistical analysis of the data submitted by the
participating centers. An overview of missing or inconsistent
data is provided to the centers every six months. If data would
be faulty, or missing, the centers are invited to correct the non-
compliance.
On-site audits are a second instrument to guarantee that data
collection and registration in the database reﬂects the reality in
the participating clinics.
. Global cooperation
In 2013, EUROMACS and IMACS signed an agreement. The
agreement sees to an annual anonymous data transfer from
EUROMACS to IMACS. Whereas IMACS’ function is to gather data
on MCS  implants on a global level, EUROMACS focuses on infor-
mation from hospitals in countries that are geographically, partly
or entirely on the European continent.
The ﬁrst IMACS report was  published early 2016, in the Journal
for Heart and Lung Transplantation.3
F. Outcomes
Fig. 1 shows the result of all MCS  implantations registered in
EUROMACS, in which the overall actuarial survival outcomes of
2174 primary implantations registered through June 6, 2016 are
depicted.
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Fig. 1. Kaplan–Meier analysis
The overall actuarial survival of 2172 MCS  patients after
6 months, 1, 2, 3, and 4 years was 78.3%, 72.9%, 62.3%, 54.9% and
44.7%, respectively. Patients at risk were 498 (at 2 years), 268 (at
3 years), and 100 (at 4 years).
Table 1 provides a break down of the INTERMACS levels of
the MCS  patients in the EUROMACS registry. The EUROMACS
database shows that 55.6% of patients with MCS  were in
INTERMACS proﬁles 2 and 3, whereas the seventh INTERMACS
report showed a total of 66.3% of patients in these two levels.4 In
comparison with the same INTERMACS report, wherein 15% of
patients were in critical cardiogenic shock at the time of implan-
tation, the EUROMACS database showed comparable 14.8% (see
Table 1) of patients in this category.
erspective
Early 2016, 47 hospitals from 17 countries contributed to the
UROMACS registry. The registered implantations exceeded 2,100,
hile the number of registered routine follow-up records and
events”, such as transplantations, adverse events, pump exchange
nd death, was more than 10,000. In the spring of 2016, a connec-
ion with the national MCS  registry of Spain, ESPAMACS, could be
stablished. Thus, participants in ESPAMACS have access to data
n a European level. This access enables them to benchmark their
esults, as well a possibility to retrieve data for scientiﬁc and/or
linical analyses.
As more individual hospitals and national databases such as the
rench, the Polish and the Dutch join the Register, it is expected that
he number of registered implantations will be more than 4000 by
017.Starting in the summer of 2016, software to execute additional
tatistical analyses, such as frequency of follow-up, ‘near real-time’
enchmarking of survival statistics and freedom of adverse events
omparisons will be introduced.
able 1
NTERMACS proﬁles of 2172 VAD implantations.
INTERMACS level n %
Critical cardiogenic shock 321 14.8
Progressive decline 658 30.3
Stable but inotrope dependent 549 25.3
Resting symptoms 363 16.7
Exertion intolerant 81 3.7
Exertion limited 35 1.6
YHA, New York Heart Association; VAD, ventricular assist device.mit Upper limit
ll survival of all MCS  devices.
As part of the EACTS, the EUROMACS Registry will be able to
beneﬁt from the technology that is being developed within the
framework of the EACTS QUIP Project. This technology will open
up new statistical pathways and interactive tools which enable e.g.
risk assessment and create possibilities for participants to diversify
their benchmarking according to patient morbidity, implant site
and size of the MCS  program.
Conclusion
The EUROMACS database provides a multi-functional tool for
cardio-thoracic surgeons, cardiologists and other professionals
who are engaged with providing care to patients with MCS. Re-
gistration in itself gives insight in the quantitative aspects of the
therapy. While some hospitals use EUROMACS to keep track of
their own  implantations and follow-up, others have the objective
to compare their outcomes with those of all participating cen-
ters. Likewise, national societies, such as the Spanish Society of
Thoracic-Cardiovascular Surgery (SECTCV) or the French SFCTCV,
may  use EUROMACS as a national database enabling measuring
the performance of all MCS  programs in the country either indi-
vidually or collectively. The link with EUROMACS, and on its turn,
the links with the EACTS and IMACS, enable all participants to
use software and data with which they can benchmark them-
selves. The tools offered make it possible to identify strengths
and weaknesses of the outcomes per hospital, or from a group
of hospitals (if all those in that group agree), and to focus on
improvements where necessary. It is expected that, over time, the
available data will contribute to beneﬁcial results for patients with
MCS.
Ethical disclosures
Protection of human and animal subjects. The authors declare
that no experiments were performed on humans or animals for
this investigation.
Conﬁdentiality of data. The authors declare that no patient data
appears in this article.Right to privacy and informed consent. The authors declare that
no patient data appears in this article.
ir Card
F
T
b
S
s
C
A
E
1
2
3
support. J Heart Lung Transplant. 2016;35:407–12, http://dx.doi.org/10.1016/
j.healun.2016.01.002T.M.M.H. de By et al. / C
unding
EUROMACS is funded by the European Association for Cardio
horacic Surgery (EACTS), the Friede-Springer-Herz-Stiftung, and
y donations of CircuLite, HeartWare, Inc., Thoratec Corporation,
yncardia and Micromed. These institutions had no inﬂuence on
tudy design, collection, analysis and interpretation of data.
onﬂict of interest
The authors declare no conﬂict of interest.cknowledgements
We  thank all institutional and individual members of
UROMACS for their continuous support and contributions.
4iov. 2016;23(S):22–25 25
References
. De By TMMH, Mohacsi P, Gummert J, Bushnaq H, Krabatsch T, Gustafsson F,
et  al. The European Registry for Patients with Mechanical Circulatory Sup-
port  (EUROMACS): ﬁrst annual report. Eur J Cardiothorac Surg. 2015;4:770–7,
http://dx.doi.org/10.1093/ejcts/ezv096
. Bernhardt AM, De By TM, Reichenspurner H, Deuse T. Isolated permanent right
ventricular assist device implantation with the HeartWare continuous-ﬂow
ventricular assist device: ﬁrst results from the European Registry for Patients
with Mechanical Circulatory Support. Eur J Cardiothorac Surg. 2015;48:158–62,
http://dx.doi.org/10.1093/ejcts/ezu406
. Kirklin JK, Cantor R, Mohacsi P, Gummert J, De By T, Hannan MM,  et al.
First Annual IMACS Report: a global ISHLT registry for mechanical circulatory. Kirklin JK, Naftel DC, Pagani FD, Kormos RL, Stevenson LW,  Blume ED, et al. Seventh
INTERMACS annual report: 15,000 patients and counting. J Heart Lung Transpl.
2015;34:1495–504.
